PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2 | 0.0% | 167 | 0.0% | 0.00% | – |
| Q2 2023 | $2 | +100.0% | 167 | 0.0% | 0.00% | – |
| Q1 2023 | $1 | -50.0% | 167 | 0.0% | 0.00% | – |
| Q4 2022 | $2 | -99.8% | 167 | +81.5% | 0.00% | – |
| Q3 2022 | $1,000 | 0.0% | 92 | 0.0% | 0.00% | – |
| Q2 2022 | $1,000 | 0.0% | 92 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | -50.0% | 92 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | – | 92 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 4,901,358 | $41,368,000 | 8.59% |
| Frazier Life Sciences Management, L.P. | 5,827,415 | $49,183,000 | 4.64% |
| Abingworth LLP | 1,435,106 | $12,112,000 | 3.88% |
| Penn Mutual Asset Management | 86,940 | $734,000 | 0.99% |
| 683 Capital Management, LLC | 1,440,000 | $12,153,000 | 0.86% |
| Western Standard LLC | 109,055 | $920,000 | 0.70% |
| MPM BioImpact LLC | 193,326 | $1,632,000 | 0.45% |
| Newtyn Management, LLC | 255,767 | $2,159,000 | 0.41% |
| StepStone Group LP | 422,085 | $3,562,000 | 0.38% |
| Avidity Partners Management LP | 1,919,800 | $16,203,000 | 0.37% |